On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayDec 21, 2016 1:16 pm

NetworkNewsBreaks – Calithera Biosciences, Inc. (NASDAQ: CALA), Bristol-Myers Squibb (NYSE: BMY) Collaborate to Assess Combination of Opdivo, CB-839

Calithera Biosciences (NASDAQ: CALA) and Bristol-Myers Squibb (NYSE: BMY) have entered into a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC). Preclinical data suggest that CB-839 – currently in phase 1/2 clinical studies - may enhance the effects of, and reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and encouraging an anti-tumor immune response. Opdivo is designed to overcome immune suppression. Under the collaboration, Calithera and Bristol-Myers will explore the potential of combining their agents with the goal of achieving improved and continual…

Continue Reading

WednesdayDec 21, 2016 1:13 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Utilizes Key Data to Reach Target Demographics in China

Moxian (NASDAQ: MOXC) is securing a foothold in the O2O (online-to-offline) market in China by paying attention to who is using O2O services, and how active those users are on social media. “Unlike in the U.S. or Europe, where O2O is often considered to be items purchased online and picked up at a store, in China O2O includes a range of categories. O2O in China takes into account travel, accommodation, transport, dinner reservations, medical appointments, and virtually any services that are ordered or booked online but paid for at point of service. With this in mind, who is the primary…

Continue Reading

WednesdayDec 21, 2016 1:11 pm

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Shares Climb After Subsidiary Launches 4TB RDX Cartridges

Shares are up 50% for Sphere 3D (NASDAQ: ANY) following the news of its wholly owned subsidiary, Tandberg Data, releasing its new 4TB RDX® cartridges. The new cartridges fit any RDX disk-based storage system, including Tandberg Data's QuikStor™ and QuikStation™.  The 4TB RDX cartridge is designed for usage in data-intensive environments, such as professional workflow and archiving, hybrid cloud applications and database seeding. The company says it has the highest capacity RDX media on the market today, increasing maximum per cartridge storage by 30 percent. To view the full press release, visit: http://nnw.fm/j8mMz About Tandberg Data Tandberg Data is a…

Continue Reading

TuesdayDec 20, 2016 2:55 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 20, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: OMTL 117.39% – News: Enters acquisition agreement ETST 21.02% – News: Developing multiple new CBD nutraceutical and pharmaceutical products BNTC 13.18%– News: Released positive in vivo model data using the company's technology to treat hepatitis B virus TVIA 9.52% – News: Suspends ingredient supply to Soylent SMDM 9.09% – News: Presenting new products at Consumer Electronics Tradeshow in Las Vegas, January 4-7, 2017 CVSI 8.24% – News: Released statement regarding many MLB stadium’s recent…

Continue Reading

TuesdayDec 20, 2016 2:34 pm

NetworkNewsBreaks – Conatus (NASDAQ: CNAT) Skyrockets on Exclusive Licensing Deal with Novartis (NYSE: NVS)

Conatus Pharmaceuticals (NASDAQ: CNAT) shares are up 141% following the early-morning announcement of an exclusive option, collaboration and license agreement with Novartis (NYSE: NVS) for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan. Per the agreement, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis. Conatus will host a conference call and webcast presentation at 5:30 p.m. ET today. “The option to co-commercialize in…

Continue Reading

TuesdayDec 20, 2016 1:37 pm

NetworkNewsBreaks – OurPet’s Company (OPCO) Sets Sights on Open Market for Interactive Dog Toys

OurPet’s Company (OTCQX: OPCO) recently opened up about the details of its continued growth in the booming non-food pet product industry. With the majority of the company’s success linked to the cat market, OPCO plans to exploit the open market for interactive dog toys. “Approximately 61% of OPCO’s revenue comes from the cat market, mostly toys and accessories together with waste and odor products, while 38% comes from the dog market, mostly feeding and storage products. However, OPCO also sees untouched opportunities in the dog toys area. As with its cat toys, OPCO has put research into the sensations and…

Continue Reading

TuesdayDec 20, 2016 1:34 pm

NetworkNewsBreaks – BioLife Solutions, Inc. (NASDAQ: BLFS) Inks Multi-Year Supply Agreement with TissueGene for CryoStor® Use in Invossa™

BioLife Solutions (NASDAQ: BLFS) is trading higher after announcing its 10-year supply agreement with TissueGene, a developer of regenerative therapies for the treatment of various orthopedic diseases. BioLife's CryoStor clinical grade cell freeze media is integrated into TissueGene's manufacturing process for Invossa, a drug designed to treat osteoarthritis of the knee through a single intra-articular injection. "We are very pleased to support TissueGene and Kolon with this long term supply agreement, which further supports our growth potential of the franchise we have built in the high growth cell therapy industry.  We believe that CryoStor and HypoThermosol are incorporated into more…

Continue Reading

TuesdayDec 20, 2016 1:31 pm

NetworkNewsBreaks – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) INSPIRE Study Reaches 50% Enrollment

InVivo Therapeutics (NASDAQ: NVIV) this morning said it has enrolled a new patient with a T8-9 fracture dislocation injury into The INSPIRE Study for the investigational Neuro-Spinal Scaffold™ at the Carolinas Medical Center in Charlotte, NC. This most recently enrolled patient marks the half-way point to full enrollment of 20 patients. “We now have ten INSPIRE patients enrolled and in follow up, which is an important milestone in this study designed to enroll 20 evaluable patients. We thank Dr. Coric and his team for having enrolled five patients at their site, and look forward to continuing to make progress toward…

Continue Reading

MondayDec 19, 2016 2:58 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 19, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SIRC 26.75% – News: Moving on momentum from recent announcement of record revenue for October, November 2016 TNXP 23.07% – News: TNX-102 SL granted Breakthrough Therapy Designation by FDA PULM 16.07%– News: Received five patents over the last 12 months for inhaled therapies CXRX 14.19% – News: Reports financial update CYRN 8.82% – News: Corporate growth driven by cyber threats, Internet vulnerabilities HOTR 7.21% – News: BGR location to open in New Jersey this…

Continue Reading

MondayDec 19, 2016 2:54 pm

NetworkNewsBreaks – Amedica Corp. (NASDAQ: AMDA) Re-submits FDA Application following Positive Scientific Data

Amedica (NASDAQ: AMDA) this morning said it has re-filed an application with the FDA following encouraging results from a recent study showing rapid bone growth into porous silicon nitride. Explants of the company's porous silicon nitride from a large-animal model demonstrated bone healing into the material just four weeks after implantation. The new submission includes a modified CsC-based cervical implant that is comparable to Amedica’s own commercially-available Valeo®C cervical implants. "With this submission, the goal is to introduce our proprietary CsC technology platform into the U.S. market without further delay," Dr. B. Sonny Bal, Amedica CEO and president, stated in…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217